Emgality administration4


  • Check the pen to be sure it is not expired, damaged, cloudy, discolored, or has particles in it
  • Choose an area for injection (abdomen or thigh if self-injecting and buttocks or back of upper arm if another person is injecting), being sure to choose a different site (even within area) each month
  • Clean the site with an alcohol wipe and let it dry before injecting

A simple approach: The 3 key administration steps1

Please review the Instructions for Use included with the pen or prefilled syringe with your patients to ensure they understand how to properly administer Emgality.

Injection Steps
Injection Steps
Injection Steps

Telephonic injection support and an injection how-to video are available to help guide your patients through self-administration.

Questions? Call 1-833-EMGALITY (1-833-364-2548).

Indications and Important Safety Information

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of migraine in adults.

Important Safety Information

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity Reactions
Hypersensitivity reactions (e.g., rash, urticaria, and dyspnea) have been reported with Emgality in clinical studies. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Emgality is available by prescription only.

Please see Full Prescribing Information, including Patient Information for Emgality. See Instructions for Use included with the pen and prefilled syringe.